News All of Ferrer’s information, just a click away Home News normal Apply Nature Medicine Publishes Phase 3 Data on Pridopidine in Early-Stage Huntington’s Disease, Highlighting Impact on Clinical Progression . Fri, 09/05/2025 - 08:15 Prilenia and Ferrer Provide Update on European Regulatory Process for Pridopidine in Huntington’s Disease . Fri, 07/25/2025 - 09:55 Ferrer strengthens its impact in 2024 with increased social and environmental investment, B Corp leadership and sustainability progress . Mon, 07/21/2025 - 17:01 We Receive FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP) . Tue, 06/17/2025 - 07:06 We enter into a collaboration and license agreement with Prilenia for the commercialization and co-development of Pridopidine . Mon, 04/28/2025 - 09:38 Experts Set International and Multidisciplinary Collaboration As Priorities in Pulmonary Hypertension Management . Wed, 04/23/2025 - 10:23 We are the highest-rated pharma B Corp in the world . Thu, 02/20/2025 - 17:03 Ferrer is recognized for its best-in-class ethics and compliance program . Thu, 01/30/2025 - 07:44 We spearhead two European studies that highlight the urgency of patients and experts to improve the diagnosis and treatment of pulmonary hypertension associated with interstitial lung disease . Wed, 11/20/2024 - 08:49 Ferrer advances research into Progressive Supranuclear Palsy (PSP) with the inclusion of the first participant in a Phase II clinical trial . Thu, 08/08/2024 - 08:36 Cargar más For requests for interviews or information, please contact the Communications Department CONTACT US alternatively, please dial +34 936 003 779 See more R&D Strategy Business Development
Nature Medicine Publishes Phase 3 Data on Pridopidine in Early-Stage Huntington’s Disease, Highlighting Impact on Clinical Progression . Fri, 09/05/2025 - 08:15
Prilenia and Ferrer Provide Update on European Regulatory Process for Pridopidine in Huntington’s Disease . Fri, 07/25/2025 - 09:55
Ferrer strengthens its impact in 2024 with increased social and environmental investment, B Corp leadership and sustainability progress . Mon, 07/21/2025 - 17:01
We Receive FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP) . Tue, 06/17/2025 - 07:06
We enter into a collaboration and license agreement with Prilenia for the commercialization and co-development of Pridopidine . Mon, 04/28/2025 - 09:38
Experts Set International and Multidisciplinary Collaboration As Priorities in Pulmonary Hypertension Management . Wed, 04/23/2025 - 10:23
We spearhead two European studies that highlight the urgency of patients and experts to improve the diagnosis and treatment of pulmonary hypertension associated with interstitial lung disease . Wed, 11/20/2024 - 08:49
Ferrer advances research into Progressive Supranuclear Palsy (PSP) with the inclusion of the first participant in a Phase II clinical trial . Thu, 08/08/2024 - 08:36